Trial
NCT04370834
Tocilizumab for Patients With Cancer and COVID-19 Disease
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
National Cancer Institute (NCI)
Collaborators
—
Condition
Hematopoietic and Lymphoid Cell Neoplasm
Intervention
Tocilizumab
Why stopped
Other - Randomized data no longer support continuation
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-02-04